nach oben

Strahlentherapie und Onkologie

Erschienen in:

01.03.2014 | Original article

Survival and prognostic factors after moderately hypofractionated palliative thoracic radiotherapy for non-small cell lung cancer

verfasst von: Dr. B. van Oorschot, B. Assenbrunner, M. Schuler, G. Beckmann, M. Flentje

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

Survival and prognostic variables in patients with advanced or metastatic non-small cell lung cancer (NSCLC) requiring thoracic palliative radiotherapy using a moderately hypofractionated regime (13–15 × 3 Gy) were evaluated.

Methods

From March 2006 to April 2012, 120 patients with a physician estimated prognosis of 6–12 months were treated with this regime using CT-based 3D conformal radiotherapy. We collected data on patient characteristics, comorbidities, toxicity, and treatment parameters.

Results

Radiotherapy was completed as prescribed in 114 patients (95.0 %, premature termination 5.0 %). Acute grade 3 toxicity was seen in 6.4 % of patients. The median survival of all patients was 5.8 months. Nonmetastatic patients survived significantly longer than patients with metastatic disease (median 11.7 months vs 4.7 months, p = 0.0001) and 18.6 % of nonmetastatic patients survived longer than 2 years. In 12.7 % radiotherapy started less than 30 days before death and 14.2 % of patients received radiotherapy within 14 days before death. In the multivariate analysis, good general condition, nonmetastatic disease, and a stable or improved general condition at the end of radiotherapy were significant. The treatment parameters, age, and comorbidities were not statistically significant.

Conclusion

Our data confirm considerable effectiveness of 13 × 3 Gy with conformal radiotherapy for patients with locally confined NSCLC not fit for radical treatment and raise doubt for this regimen in metastatic patients and ECOG ≥ 2 when burden, acute toxicity, and resources are considered.

Beli I, Koukourakis G, Platoni K et al (2010) Hypofractionated radiotherapy in non small cell lung cancer: a review of the current literature. Rev Recent Clin Trials 5(2):103–111PubMedCrossRef

Berghmans T, Paesmans M, Sculier JP (2011) Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables. Ther Adv Med Oncol 3(3):127–138PubMedCentralPubMedCrossRef

Bleher M, Bratengeier K, Richter J (1991) Assessment of radiotherapy plans: dose–volume histograms, integral effects and tumor control. Strahlenther Onkol 167(4):220–226PubMed

Campion FX, Larson LR, Kadlubek PJ et al (2011) Advancing performance measurement in oncology: quality oncology practice initiative participation and quality outcomes. J Oncol Pract 7(3 Suppl):31s–35sPubMedCentralPubMedCrossRef

Charlson ME, Pompei P, Ales KL et al (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383PubMedCrossRef

Chen AB, Cronin A, Weeks JC et al (2013) Palliative radiation therapy practice in patients with metastatic non-small-cell lung cancer: a Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) Study. J Clin Oncol 31(5):558–564PubMedCentralPubMedCrossRef

Chow E, Abdolell M, Panzarella T et al (2009) Validation of a predictive model for survival in metastatic cancer patients attending an outpatient palliative radiotherapy clinic. Int J Radiat Oncol Biol Phys 73(1):280–287PubMedCrossRef

Colinet B, Jacot W, Bertrand D et al (2005) A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson’s index. Br J Cancer 93(10):1098–1105PubMedCentralPubMedCrossRef

De Rijke JM, Schouten LJ, Velde GP ten et al (2004) Influence of age, comorbidity and performance status on the choice of treatment for patients with non-small cell lung cancer; results of a population-based study. Lung Cancer 46(2):233–245CrossRef

10.

Duncker-Rohr V, Nestle U, Momm F et al (2013) Stereotactic ablative radiotherapy for small lung tumors with a moderate dose. Favorable results and low toxicity. Strahlenther Onkol 189(1):33–40PubMedCrossRef

11.

Earle CC, Park ER, Lai B et al (2003) Identifying potential indicators of the quality of end-of-life cancer care from administrative data. J Clin Oncol 21(6):1133–1138PubMedCrossRef

12.

Edge SB, Byrd DR, Compton CC et al (eds) (2010) AJCC Cancer Staging Manual, 7th edn. Springer, New York

13.

Enders CK (2010) Applied missing data analysis. Guilford, New York

14.

Erridge SC, Gaze MN, Price A et al (2005) Symptom control and quality of life in people with lung cancer: a randomised trial of two palliative radiotherapy fractionation schedules. Clin Oncol (R Coll Radiol) 17(1):61–67

15.

Fairchild A, Harris K, Barnes E et al (2008) Palliative thoracic radiotherapy for lung cancer: a systematic review. J Clin Oncol 26(24):4001–4011PubMedCrossRef

16.

Fromme EK, Smith MD, Bascom PB et al (2010) Incorporating routine survival prediction in a U.S. hospital-based palliative care service. J Palliat Med 13(12):1439–1444PubMedCentralPubMedCrossRef

17.

Gironés R, Torregrosa D, Gómez-Codina J et al (2011) Prognostic impact of comorbidity in elderly lung cancer patients: use and comparison of two scores. Lung Cancer 72(1):108–113PubMedCrossRef

18.

Giroux Leprieur E, Lavole A, Ruppert AM et al (2012) Factors associated with long-term survival of patients with advanced non-small cell lung cancer. Respirology 17(1):134–142CrossRef

19.

Glare PA, Sinclair CT (2008) Palliative medicine review: prognostication. J Palliat Med 11(1):84–103PubMedCrossRef

20.

Goeckenjan G, Sitter H, Thomas M et al (2011) Prevention, diagnosis, therapy, and follow-up of lung cancer: interdisciplinary guideline of the German Respiratory Society and the German Cancer Society. Pneumologie 65(1):39–59PubMedCrossRef

21.

Graham JW (2009) Missing data analysis: making it work in the real world. Annu Rev Psychol 60:549–576PubMedCrossRef

22.

Greer JA, Pirl WF, Jackson VA et al (2012) Effect of early palliative care on chemotherapy use and end-of-life care in patients with metastatic non-small-cell lung cancer. J Clin Oncol 30(4):394–400PubMedCrossRef

23.

Gripp S, Moeller S, Bölke E et al (2007) Survival prediction in terminally ill cancer patients by clinical estimates, laboratory tests, and self-rated anxiety and depression. J Clin Oncol 25(22):3313–3320PubMedCrossRef

24.

Gripp S, Mjartan S, Boelke E et al (2010) Palliative radiotherapy tailored to life expectancy in end-stage cancer patients. Cancer 116:3251–3256PubMedCrossRef

25.

Grose D, Devereux G, Milroy R (2011) Comorbidity in lung cancer: important but neglected. A review of the current literature. Clin Lung Cancer 12(4):207–211PubMedCrossRef

26.

Guadagnolo BA, Liao KP, Elting L et al (2013) Use of radiation therapy in the last 30 days of life among a large population-based cohort of elderly patients in the United States. J Clin Oncol 31(1):80–87PubMedCentralPubMedCrossRef

27.

Jacot W, Colinet B, Bertrand D et al (2008) Quality of life and comorbidity score as prognostic determinants in non-small-cell lung cancer patients. Ann Oncol 19(8):1458–1464PubMedCrossRef

28.

Kramer GW, Wanders SL, Noordijk EM et al (2005) Results of the Dutch National study of the palliative effect of irradiation using two different treatment schemes for non-small-cell lung cancer. J Clin Oncol 23(13):2962–2970PubMedCrossRef

29.

Lester JF, Macbeth FR, Toy E et al (2006) Palliative radiotherapy regimens for non-small cell lung cancer. Cochrane Database Syst Rev 18:(4):CD002143

30.

n A (1991) Inoperable non-small-cell lung cancer (NSCLC): a Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractions. Report to the Medical Research Council by its Lung Cancer Working Party. Br J Cancer 63(2):265–270CrossRef

31.

Lutz T, Chow L, Hartsell W et al (2007) A review of hypofractionated palliative radiotherapy. Cancer 109(8):1463–1469CrossRef

32.

Mac Manus MP, Matthews JP, Wada M et al (2001) Palliative radiotherapy regimens for non-small cell lung cancer. Cochrane Database Syst Rev 3:CD002143 (Review. Update in: Cochrane Database Syst Rev 2006)

33.

Maltoni M, Caraceni A, Brunelli C et al (2005) Prognostic factors in advanced cancer patients: evidence-based clinical recommendations—a study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol 23(25):6240–6248PubMedCrossRef

34.

Maurer J, Hipp M, Schäfer C et al (2011) Dysphagia. Impact on quality of life after radio(chemo)therapy of head and neck cancer. Strahlenther Onkol 187(11):744–749PubMedCrossRef

35.

National Comprehensive Cancer Network (NCCN) Guidelines Non-Small Cell Lung Cancer, Version 2.2013. http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed 31 December 2013

36.

Nestle U, Nieder C, Walter K et al (2000) A palliative accelerated irradiation regimen for advanced non-small-cell lung cancer vs. conventionally fractionated 60 Gy: results of a randomized equivalence study. Int J Radiat Oncol Biol Phys 48(1):95–103PubMedCrossRef

37.

Numico G, Russi E, Merlano M (2001) Best supportive care in non-small cell lung cancer: is there a role for radiotherapy and chemotherapy? Lung Cancer 32(3):213–226PubMedCrossRef

38.

Read WL, Tierney RM, Page NC et al (2004) Differential prognostic impact of comorbidity. J Clin Oncol 22(15):3099–3103PubMedCrossRef

39.

Reinfuss M, Mucha-Małecka A, Walasek T et al (2011) Palliative thoracic radiotherapy in non-small cell lung cancer. An analysis of 1250 patients. Palliation of symptoms, tolerance and toxicity. Lung Cancer 71(3):344–349PubMedCrossRef

40.

Rodrigues G, Macbeth F, Burmeister B et al (2012) International practice survey on palliative lung radiotherapy: third international consensus workshop on palliative radiotherapy and symptom control. Clin Lung Cancer 13(3):225–235PubMedCrossRef

41.

Salvo N, Hadi S, Napolskikh J et al (2009) Quality of life measurement in cancer patients receiving palliative radiotherapy for symptomatic lung cancer: a literature review. Curr Oncol 16(2):16–28PubMedCentralPubMed

42.

Schröder C, Ivo M, Buchali A (2013) Does high-dose radiotherapy benefit palliative lung cancer patients? An intradepartmental comparison of two dose regimens. Strahlenther Onkol 189(9):771–776PubMedCrossRef

43.

Smith SL, Palma D, Parhar T et al (2011) Inoperable early stage non-small cell lung cancer: comorbidity, patterns of care and survival. Lung Cancer 72(1):39–44PubMedCrossRef

44.

Tang JI, Shakespeare TP, Lu JJ et al (2008) Patients’ preference for radiotherapy fractionation schedule in the palliation of symptomatic unresectable lung cancerdagger. J Med Imaging Radiat Oncol 52(5):497–502PubMedCrossRef

45.

Temel JS, Greer JA, Muzikansky A et al (2010) Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 363(8):733–742PubMedCrossRef

46.

Timothy AR, Girling DJ, Saunders MI et al (2001) Radiotherapy for inoperable lung cancer. Clin Oncol (R Coll Radiol) 13(2):86–87

47.

Trotti A, Colevas AD, Setser A et al (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13(3):176–181PubMedCrossRef

48.

Toole M, Lutz S, Johnstone PA (2012) Radiation oncology quality: aggressiveness of cancer care near the end of life. J Am Coll Radiol 9(3):199–202PubMedCrossRef

49.

Turner NJ, Muers MF, Haward RA, Mulley GP (2005) Do elderly people with lung cancer benefit from palliative radiotherapy? Lung Cancer 49(2):193–202PubMedCrossRef

50.

Oorschot B van, Rades D, Schulze W et al (2011) Palliative radiotherapy: new approaches. Semin Oncol 38(3):443–449PubMedCrossRef

51.

Oorschot B van, Schuler M, Simon A et al (2011) Patterns of care and course of symptoms in palliative radiotherapy: a multicenter pilot study analysis. Strahlenther Onkol 187(8):461–466PubMedCrossRef

52.

Wang T, Nelson RA, Bogardus A, Grannis FW Jr (2010) Five-year lung cancer survival: which advanced stage nonsmall cell lung cancer patients attain long-term survival? Cancer 116(6):1518–5125PubMedCrossRef

Titel: Survival and prognostic factors after moderately hypofractionated palliative thoracic radiotherapy for non-small cell lung cancer
verfasst von: Dr. B. van Oorschot
B. Assenbrunner
M. Schuler
G. Beckmann
M. Flentje
Publikationsdatum: 01.03.2014
Verlag: Springer-Verlag
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 3/2014
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-013-0507-y

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Survival and prognostic factors after moderately hypofractionated palliative thoracic radiotherapy for non-small cell lung cancer

Abstract

Background

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2014

Concomitant chemoradiotherapy versus induction chemotherapy followed by chemoradiotherapy as definitive, first line treatment of squamous cell carcinoma of the head and neck

Erratum to: Prognostic impact of VEGF and FLT-1 receptor expression in patients with locally advanced squamous cell carcinoma of the head and neck

Erratum to: Impact of the HPV-positivity definition on the prognostic value of HPV status in patients with locally advanced squamous cell carcinoma of the head and neck

A pilot study on potential plasma hypoxia markers in the radiotherapy of non-small cell lung cancer

Concurrent hyperfractionated accelerated radiotherapy with 5-FU and once weekly cisplatin in locally advanced head and neck cancer

Target volume coverage and dose to organs at risk in prostate cancer patients

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie